Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Biohaven Ltd.

Get SEC filing alerts via email and in your feed for Biohaven Ltd.

BHVN

Biohaven Ltd.

About Biohaven Ltd.

Biohaven Ltd. is a biopharmaceutical company specializing in the discovery, development, and commercialization of innovative therapies across neuroscience, immunology, and oncology. Its core portfolio includes glutamate modulators for neurological disorders, myostatin inhibitors for neuromuscular and metabolic diseases, and Kv7 ion channel activators for epilepsy and mood disorders. Biohaven targets patients with rare and complex conditions, leveraging proprietary drug platforms and clinical expertise to address unmet medical needs globally.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Biohaven Ltd.

1
1
Biohaven Ltd. Biohaven Reports Improved Q1 2026 Financial Results with $130.5M Net Loss

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Biohaven Ltd. Biohaven Reports $738.8 Million Net Loss for 2025, Focuses on Key Clinical Programs

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Biohaven Ltd. Biohaven Reports $173.4 Million Net Loss in Q3 2025, Decreases Operating Expenses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Biohaven Ltd. Biohaven Reports Q2 2025 Financial Results with Improved Net Loss of $198.1 Million

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Biohaven Ltd. Biohaven Reports $221.7 Million Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Biohaven Ltd. Biohaven Reports $846.4 Million Net Loss for Year Ended December 31, 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Biohaven Ltd. Biohaven Reports Significant Operating Expenses and Net Losses in Q3 2024, Completes Acquisition and Raises Capital

Via official filing (AI summary) | over 1 year ago | 0 comments